$TP

Ticketplus files for IPO on NYSE American at up to $15 per share By Investing.com

Ticketplus Ltd. filed for an IPO on NYSE American to sell 1,786,000 ordinary shares at an estimated $13.00–$15.00 per share, with a $14.00 midpoint used for prospectus estimates, according to its filing. The shares would trade under ticker TP, pending exchange approval. Roth Capital Partners, Bancroft Capital LLC, and MDB Capital are underwriters.

Original reporting
Published Jul 2, 2026, 8:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 2, 2026, 8:18 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefIPO
Primary signal
$TP
Neutral
medium confidence
Mentioned
$TP
Relevance
6/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$TPNeutralMed
01

Why it matters

The key tradable variable is the path from filing → listing approval → pricing. Without financial metrics or priced valuation, the article mainly informs event timing and potential volatility rather than intrinsic value.

02

Market read

New IPO filing with a defined price range and listing ticker can drive pre-pricing positioning and first-day expectations, but lacks priced valuation or fundamentals.

03

What to watch

Traders should focus on subsequent prospectus amendments, bookbuilding demand, and any changes to the $13-$15 range or underwriter syndicate rather than the midpoint.

Relevance 6/10Novelty 8/10Timing: IPO filing/prospectus details ahead of NYSE American listing approval and future pricing

Background

Ticketplus says there has been no prior public market for its shares; it filed a prospectus and applied to list on NYSE American.

Company-level read

Ticker impact

$TPNeutralMedium confidence
Context

Ticketplus filed for an IPO of 1,786,000 shares with an estimated $13-$15 range and applied to list on NYSE American as TP.

Expected impact

Likely limited immediate impact until pricing/terms are updated; volatility risk increases into the listing approval and bookbuild.

Evidence & confidence

The article discloses a fresh prospectus filing and listing application, but no priced deal, financials, or guidance—so impact is mostly event-driven rather than fundamental.

Market effects

Adds another microcap/small-cap IPO candidate, but no sector-specific fundamentals are provided.

US listing venue (NYSE American) may attract small-cap IPO flow attention; no broader index linkage stated.

No cross-border deal or macro linkage mentioned beyond the US listing process.

Counterpoint

An IPO filing alone can be a low-signal event—terms can change materially, and approval/timing uncertainty can reduce tradability.

Key entities

  • Ticketplus Ltd.

    Filed for an IPO of 1,786,000 ordinary shares with an estimated $13.00-$15.00 price range; applied to list on NYSE American under ticker TP.

  • Roth Capital Partners

    Named as an underwriter for the offering.

  • Bancroft Capital LLC

    Named as an underwriter for the offering.

  • MDB Capital

    Named as an underwriter for the offering.

Related articles

$TPMedAI 8/10

Air France-KLM, Lufthansa Group submit binding bids for TAP

Air France-KLM and Lufthansa Group submitted binding bids to buy 44.9% to 49.9% of TAP Air Portugal from Portugal’s state holding Parpública, without disclosing bid values. Both said they would preserve Lisbon as a hub and expand connectivity, including transatlantic routes. Air France-KLM cited MRO investment plans supported by Delta Air Lines; Lufthansa said TAP is already in Star Alliance and Lisbon would focus on South America.

$SECZMed

Securitize Lists on NYSE and Tokenizes Its Own Stock on Day 1

Securitize (SECZ) began trading on the NYSE at $12.45, closing at $12.30. It also tokenized its stock on Solana and Avalanche, with $295M in tokenized shares at launch. The company aims to tokenize IPO allocations for crypto investors, targeting transactions within 3-6 months. Securitize reported $3.4B in tokenized assets and $19.5M in Q1 2026 revenue, up 39% YoY.

$SWMRHigh

Why SWMR Stock Soared Over 500% In Nasdaq Debut Today

Swarmer, Inc. (SWMR) shares surged 520% in its Nasdaq debut, closing at $31 after pricing its IPO at $5 per share, raising $15 million. The company, which develops drone software, plans to use proceeds for operations and expansion. Revenue was $309,920 in 2025, with a net loss of $8.5 million. CEO Alex Fink highlighted global demand driven by conflicts and the need for battlefield automation.

$ODTXHighAI 8/10

Odyssey Therapeutics Hits $900M Valuation In Nasdaq Debut, Stock Climbs 13% Before Diving Lower

Odyssey Therapeutics (ODTX) debuted on Nasdaq at $20, raising $279M via an upsized offering. Shares initially climbed 13% but later fell 10% to $16. The company also raised $25M in a private placement, totaling $304M. Proceeds will fund drug development, including OD-001 for ulcerative colitis and Crohn's disease. The company reported net losses of $148.6M in 2025 and $129.3M in 2024, with $175.7M in cash as of March 2026.